CinPressa

CinPressa is a clinical-stage biotechnology company and a portfolio company of CinRx Pharma, focused on developing improved treatments for pulmonary arterial hypertension (PAH). The company's lead program, CIN-103, is a novel, room-temperature stable formulation of epoprostenol designed to overcome the stability and delivery challenges associated with current prostacyclin therapies. By providing a more stable and convenient formulation, CinPressa aims to improve the quality of life and treatment adherence for patients requiring continuous infusion therapy. The company leverages the centralized resources and expertise of the CinRx ecosystem to accelerate the development of its cardiovascular and pulmonary pipeline. CinPressa is currently advancing its lead candidate through clinical trials to demonstrate its potential as a best-in-class therapy for PAH patients.